#Germany #Evotec #Hamburg #Plectonic #LOGIBODY

Evotec and Plectonic Collaborate on T-Cell Engaging Therapies for Solid Tumors

In the realm of cancer treatment, harnessing the body’s immune system to target tumors effectively has been a growing area of research. Recently, Evotec SE and Plectonic Biotech have announced a partnership to delve deeper into T-cell engagers designed specifically for solid tumors. This collaboration promises to address the significant challenges present in traditional immunotherapies, especially where solid tumors are concerned, which account for around 90% of all cancers.

The Partnership Depth

The collaboration aims to combine Plectonic's innovative LOGIBODY® technology with Evotec's BiTco platform to create a new class of immunotherapy. By integrating these two advanced technologies, they will work towards enhancing the precision and effectiveness of T-cell activation against tumors. Plectonic's LOGIBODY® is engineered as a DNA-protein therapeutic that requires a combination of tumor-associated antigens for T-cell activation, thereby improving specificity and safety.

Evotec's BiTco platform utilizes a non-blocking CD2 antibody designed to provide additional costimulatory signals, thereby boosting T-cell activity and longevity within the tumor microenvironment. Together, their goal is to create a synergistic effect - using LOGIBODY® for specific tumor targeting while BiTco enhances T-cell engagement and efficiency.

Why Solid Tumors are Tough to Treat

Despite advancements in oncology, solid tumors present unique challenges. Traditional T-cell engaging therapies have seen success in hematological cancers, but translating these successes to solid cancers has proven difficult. Factors such as tumor microenvironments that often suppress immune responses, and the heterogeneity of tumor cells, complicate treatment options and outperform results.

Dr. Cord Dohrmann, Evotec’s Chief Scientific Officer, underscores the potential of this partnership, stating that they are hoping to translate the promise seen in blood cancers to solid tumors, which need a robust immunotherapeutic solution. The hope is that through their collaborative efforts, they can create an effective method for engaging T-cells more precisely and effectively against solid tumors.

Advanced Immunotherapy Approaches

The collaboration not only aims to yield preclinical proof-of-concept data but also to explore innovative strategies that can enhance T-cell engager performance. By employing Plectonic’s logic-gated approach, which mandates T-cell activation through a specific multi-antigen signature, combined with Evotec’s costimulatory technology, they will explore new pathways to enhance how the immune system works against cancer.

Dr. Klaus Wagenbauer, CEO of Plectonic, expresses excitement about this endeavor, emphasizing that their technology’s modularity offers vast potential to build biologics that can operate under precise conditions, potentially minimizing off-target effects that have limited past T-cell therapies’ success.

Exploring New Frontiers in Cancer Therapy

As the partnership unfolds, both companies are focused on addressing historical limitations in T-cell engaging therapies. Plectonic’s preclinical studies utilizing dual-targeting approaches and Evotec's established research on their BiTco platform pose an exciting opportunity for breakthroughs not just in solid tumors, but across various types of cancers.

Ultimately, this collaboration represents a forward step in cancer therapy development. With innovative technologies at their disposal, Evotec and Plectonic are poised to change the landscape of how solid tumors are approached, improving patient outcomes and propelling forward the field of immunotherapy.

For those invested in the ongoing battle against cancer, this partnership exemplifies how strategic scientific collaborations can yield significant advances in treatment methodologies. As research continues, the medical community eagerly anticipates the discoveries that may arise from this innovative alliance.